Safety and Efficacy of Prophylactic Defibrotide in Patients With Sickle Cell Disease Following Myeloablative Conditioning and Haploidentical Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Defibrotide (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- 05 May 2017 Status changed from not yet recruiting to recruiting.
- 20 Sep 2016 Planned initiation date changed from 1 Feb 2016 to 1 Nov 2016.
- 18 Feb 2016 New trial record